2024-03-06 23:17:10 ET
Zymeworks Inc. (ZYME)
Q4 2023 Earnings Conference Call
March 6, 2024, 4:30 PM ET
Company Participants
Shrinal Inamdar - Director, Investor Relations
Dr. Chris Astle - Senior Vice President and CFO
Paul Moore - Chief Scientific Officer
Ken Galbraith - Chair and CEO
Conference Call Participants
Stephen Willey - Stifel
Ivy Wang - Jefferies
Yigal Nochomovitz - Citigroup
Brian Cheng - JPMorgan
Jon Miller - Evercore ISI
Presentation
Operator
Thank you for standing by. This is the conference operator. Welcome to Zymeworks Fourth Quarter and Year End 2023 Results Conference Call and Webcast. As a reminder, all participants are in a listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. [Operator Instructions]
I would now like to turn the conference over to Shrinal Inamdar, Director of Investor Relations. Shrinal, please go ahead.
Shrinal Inamdar
Thank you, Operator. Good afternoon. I’d like to welcome you all to our fourth quarter and year-end 2023 results conference call.
Before we begin, I’d like to remind you that we’ll be making a number of forward-looking statements during this call, including without limitation, those forward-looking statements identified in our presentation slides and the accompanying oral commentary.
These forward-looking statements are based upon our current expectations and various assumptions, and are subject to the usual risks and uncertainties associated with companies in our industry and at our stage of development. For discussion of these risks and uncertainties, we refer you to our latest SEC filings as found on our website and as part of the SEC.
In a moment, I’ll hand over to Dr. Chris Astle, our Senior Vice President and Chief Financial Officer, who will be discussing recent scientific and corporate updates, along with our financial results for the fourth quarter 2023, including certain non-GAAP measures.
A description of our non-GAAP measures and a reconciliation to the most directly comparable financial measures as determined in accordance with GAAP are described in our press release, which is available on our website at www.zymeworks.com under the Investor Relations tab.
Following this, Paul Moore, our Chief Scientific Officer, will talk about key expected milestones that underpin another potentially transformative year for Zymeworks, both through expected upcoming regulatory approvals and launches, and more broadly through executing on our development strategy for our early-stage product candidates.
At the end of the call, Chris and Paul will be joined by our Chair and Chief Executive Officer, Ken Galbraith, for Q&A. As a reminder, the audio and slides from this call will also be available on the Zymeworks website later today....
Read the full article on Seeking Alpha
For further details see:
Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript